Drug Profile
Research programme: recombinant human factor VIII - GTC Biotherapeutics/ProGenetics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator ProGenetics
- Developer ProGenetics; rEVO Biologics
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Haemophilia-A in USA (Parenteral)
- 07 Dec 2010 GTC Biotherapeutics has been acquired by LFB Biotechnologies
- 06 Dec 2007 Recombinant human factor VIII, factor IX and fibrinogen licensed to GTC Biotherapeutics in North America, Europe and Japan